One hundred and twenty-six patients undergoing arthroscopic knee surgery were randomized in this non-inferiority trial to receive either imrecoxib (n=64) or celecoxib (n=62). The primary outcome of interest pain scores on a Visual Analog Scale (VAS), measured at rest and during movement up to 72 hours post-operation. Secondary outcomes of interest included pethidine administration, patient satisfa...